Company
Headquarters: New York, NY, United States
Employees: 33
CEO: Mr. Gerard J. Michel
$221.2 Million
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Abbott | $178.02 B |
Stryker Corporation | $126.48 B |
Boston Scientific Corporation | $112.32 B |
Medtronic | $98.95 B |
Edwards Lifesciences Corporation | $55.63 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Delcath Systems, Inc. has the following listings and related stock indices.
Stock: NASDAQ: DCTH wb_incandescent
Stock: OTC: DCTH wb_incandescent
Pharmaceutical and medical device company focused on oncology